MedTrace Logo

Tirzepatide vs Liraglutide in Bone

NCT07094568 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2026-01-21

No results posted yet for this study

Summary

This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.

Conditions

  • Obesity (Disorder)

Sponsors & Collaborators

  • Laikο General Hospital, Athens

    collaborator OTHER

  • Athens Medical Center

    collaborator OTHER

  • Sotiria General Hospital

    collaborator OTHER

  • 251 Hellenic Air Force & VA General Hospital

    collaborator OTHER

  • Evangelismos Hospital

    collaborator OTHER

  • National and Kapodistrian University of Athens

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-23
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07094568 on ClinicalTrials.gov